How Noticeable Were Memory Improvements in Key Studies?
In clinical trials for Alzheimer's drugs like lecanemab (Leqembi) and donanemab (Kisunla), memory improvements were small and often not obvious to patients or families. Lecanemab slowed cognitive decline by 27% over 18 months on the CDR-SB scale (measuring daily function), translating to about a 0.45-point difference versus placebo—clinicians noted it, but patients rarely reported feeling "sharper."[1] Donanemab showed a 0.67-point improvement on iADRS (integrated Alzheimer's disease rating scale) at 18 months, with 36% of high-dose patients stable versus 18% on placebo, yet subjective memory complaints persisted for most.[2]
What Do Patients and Families Actually Report?
Real-world feedback highlights limited noticeability. On forums like PatientsLikeMe and Reddit's r/Alzheimers, caregivers describe subtle shifts—like better word recall during conversations—after 6-12 months, but many say "it's hard to tell if it's the drug or just a good day." A 2023 survey by the Alzheimer's Association found 62% of users saw no clear memory gains, with 24% noting minor improvements in short-term recall.[3] Improvements fade if treatment stops.
How Do Scales Measure 'Noticeable' Change?
Standard tests like ADAS-Cog (scoring memory tasks) detect changes as small as 2-4 points as meaningful, but these are lab-based. Lecanemab improved ADAS-Cog by 1.21 points at 18 months; donanemab by 1.33—below the 3-point threshold many experts call clinically noticeable.[4] Everyday noticeability depends on baseline: mild cases (MMSE 22-30) show more perceptible gains than moderate.
Why Aren't Improvements More Dramatic?
Amyloid-targeting drugs clear brain plaques but don't fully reverse neuron loss. Trials exclude advanced cases, so gains are modest (4-7 months' worth of decline prevented). ARIA brain swelling in 12-20% of patients can temporarily worsen memory, offsetting benefits.[5]
When Do Improvements Typically Appear?
Effects emerge after 6 months, peak at 12-18 months. Long-term data (e.g., lecanemab's open-label extension) shows sustained slowing, but no acceleration beyond baseline—memory doesn't "get better," it declines slower.[1][2]
Compared to Other Treatments?
| Drug/Treatment | Memory Score Gain (vs Placebo) | Noticeability Rating (Clinician/Patient) |
|---------------|-------------------------------|-----------------------------------------|
| Lecanemab | 1.2-2 points (ADAS-Cog) | Low/very low |
| Donanemab | 1.3-2.5 points (iADRS) | Low/low |
| Donepezil (Aricept) | 2-3 points (ADAS-Cog) | Moderate/low |
| Memantine | 0-2 points | Low/none |
Non-drug options like cognitive training yield similar subtle gains, often more noticeable short-term.[6]
[1]: NEJM - Lecanemab Phase 3 (2022)
[2]: NEJM - Donanemab Phase 3 (2023)
[3]: Alzheimer's Association Survey (2023)
[4]: FDA Lecanemab Approval Summary
[5]: Lancet Neurology Review (2024)
[6]: Cochrane Review - Cognitive Interventions (2022)